Profitelligence Profitelligence · Filing Ledger Open MRNA research →

Form 8-K · Current Report · Filed 2025-05-05

Moderna Stockholders Approve Key Proposals at 2025 Annual Meeting

On April 30, 2025, Moderna, Inc. held its Annual Meeting of Stockholders where key proposals were approved. Stockholders elected three directors: Noubar Afeyan, Stéphane Bancel, and François Nader. An advisory vote approved the compensation of named executive officers, and the appointment of Ernst & Young LLP as the independent registered public accounting firm was ratified.

Filer
Moderna Inc. MRNA · NASDAQ
Filed
Accession
0001682852-25-000036
CIK
0001682852
Signal
Medium impactHealthcare

Items reported

Item 5.07

Submission of Matters to a Vote of Security Holders

Director Elections Results Say-on-Pay Approved Proxy Battle Won

Market reaction

Close before filing

$27.61

Next session

-11.5%

Since filing

+98.6%

Latest close

$54.82

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from MRNA reporting the same item, with the next session's move:

About Moderna Inc.

Moderna Inc. is a biotechnology company focused on developing transformative medicines based on messenger RNA (mRNA) technology. Its primary function is to research and produce a broad spectrum of vaccines and therapeutics by leveraging its proprietary mRNA technology platform. Moderna is notably recognized for its pivotal role in the healthcare and pharmaceutical sector, particularly due to its development of one of the first COVID-19 vaccines to receive emergency use authorization. The company’s pipeline extends beyond infectious diseases, targeting therapeutic areas such as oncology, cardiovascular diseases, and rare genetic disorders. Headquartered in Cambridge, Massachusetts, Moderna takes a leading position in the biotechnology industry through its innovative approach to drug development, emphasizing rapid advancement from concept to clinical application. The company plays a crucial role in addressing global health challenges through its cutting-edge mRNA-based solutions.

Exchange NASDAQ Industry Biotechnology Company website ↗

Never miss another MRNA filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts